/IMUX
IMUX Stock - Immunic, Inc.
Healthcare|BiotechnologyNASDAQ
$0.57+1.13%
+$0.01 (+1.13%) • Dec 19
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.61
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+772.6%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IMUX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.57 – $0.58
TARGET (TP)$5.00
STOP LOSS$0.53
RISK/REWARD1:103.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.49
52W High$1.39
52W Low$0.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-98,052,000 | $-99,223,000 | $-119,488,000 | $-91,665,000 | $-48,971,000 |
| Net Income | $-100,507,000 | $-93,612,000 | $-120,407,000 | $-92,945,000 | $-44,017,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.00 | $-2.11 | $-3.78 | $-3.92 | $-2.81 |
Company Overview
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish0 Neutral/Bearish
Price Targets
$10
Average Target
↑ 1595.3% Upside
Now
$3
Low
$10
Average
$26
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 7th 2025 | Roth Capital | Initiation | Buy | $3 |
| September 29th 2025 | Chardan Capital Markets | Initiation | Buy | $13 |
| March 25th 2025 | William Blair | Initiation | Outperform | - |
| November 25th 2024 | H.C. Wainwright | Initiation | Buy | $10 |
| September 9th 2024 | Leerink Partners | Resumed | Outperform | $5 |
| August 27th 2024 | B. Riley Securities | Initiation | Buy | $6 |
| October 21st 2022 | SVB Leerink | Downgrade | Market Perform | $5 |
| September 19th 2022 | H.C. Wainwright | Resumed | Buy | $26 |
Earnings History & Surprises
IMUXBeat Rate
39%
Last 18 quarters
Avg Surprise
-6.2%
EPS vs Estimate
Beats / Misses
7/10
1 met exactly
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q1 24
+5.9%
$-0.48vs$-0.51
Q2 24
+7.4%
$-0.25vs$-0.27
Q3 24
+8.7%
$-0.21vs$-0.23
Q4 24
-9.1%
$-0.24vs$-0.22
Q1 25
-13.6%
$-0.25vs$-0.22
Q2 25
0.0%
$-0.25vs$-0.25
Q3 25
-11.1%
$-0.20vs$-0.18
Q4 25
+27.8%
$-0.13vs$-0.18
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.10 | — | — | — |
Q1 2026 | Feb 19, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.18 | $-0.13 | +27.8% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.18 | $-0.20 | -11.1% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.25 | $-0.25 | 0.0% | = MET |
Q1 2025 | Mar 27, 2025 | $-0.22 | $-0.25 | -13.6% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.51 | $-0.48 | +5.9% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.55 | $-0.51 | +7.3% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.52 | $-0.54 | -3.8% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.54 | $-0.58 | -7.4% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.82 | $-1.63 | -98.8% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.64 | $-0.69 | -7.8% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.68 | $-0.72 | -5.9% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.80 | $-0.74 | +7.5% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.73 | $-0.81 | -11.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.81 | $-0.76 | +6.2% | ✓ BEAT |
Q3 2021 | Aug 6, 2021 | $-0.72 | $-0.82 | -13.9% | ✗ MISS |
Latest News
HC Wainwright & Co. Maintains Buy on Immunic, Lowers Price Target to $8
📈 PositiveBenzinga•Nov 14, 2025, 01:02 PM
D. Boral Capital Maintains Buy on Immunic, Lowers Price Target to $8
➖ NeutralBenzinga•Nov 13, 2025, 01:47 PM
Immunic Q3 EPS $(0.13) Beats $(0.18) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 11:33 AM
Chardan Capital Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $3
📈 PositiveBenzinga•Sep 29, 2025, 11:28 AM
HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $10 Price Target
📈 PositiveBenzinga•Sep 26, 2025, 10:39 AM
D. Boral Capital Maintains Buy on Immunic, Maintains $10 Price Target
📈 PositiveBenzinga•Sep 25, 2025, 12:04 PM
Immunic Showcases Vidofludimus Calcium's MS Potential In Oral And Poster Presentations, Including Late-Breaker, At ECTRIMS 2025
📈 PositiveBenzinga•Sep 25, 2025, 10:33 AM
Immunic Secures New US Patent Protection for Multiple Sclerosis Drug Vidofludimus Calcium Through 2041
📈 PositiveBenzinga•Sep 9, 2025, 10:32 AM
Immunic shares fall 12% after pricing of $65 million underwritten public offering to fund trials
📉 NegativeSeeking Alpha•May 29, 2025, 12:41 PM
Immunic launches public offering of warrants to fund clinical trials; shares down
📉 NegativeSeeking Alpha•May 28, 2025, 08:59 PM
Immunic drops after mid-stage trial data for multiple sclerosis drug
📉 NegativeSeeking Alpha•Apr 30, 2025, 12:07 PM
Frequently Asked Questions about IMUX
What is IMUX's current stock price?
Immunic, Inc. (IMUX) is currently trading at $0.57 per share. The stock has moved +1.13% today.
What is the analyst price target for IMUX?
The average analyst price target for IMUX is $5.00, based on 1 analyst.
What sector is Immunic, Inc. in?
Immunic, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IMUX's market cap?
Immunic, Inc. has a market capitalization of $0.06 billion, making it a small-cap company.
Does IMUX pay dividends?
No, Immunic, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACET
Adicet Bio, Inc.
$0.49
Mkt Cap: $0.0B
ACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
BMEA
Biomea Fusion, Inc.
$1.40
Mkt Cap: $0.1B
CBUS
Cibus, Inc.
$1.71
Mkt Cap: $0.1B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
VXRT
Vaxart, Inc.
$0.35
Mkt Cap: $0.1B
Explore stocks similar to IMUX for comparison